Cargando…
Annual reports in medicinal chemistry. Volume 49 /
Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry with an emphasis on emerging topics in the biological sciences that are expected to provide the basis for entirely new future therapies. Reviews on hot topics of interest in small mo...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Amsterdam :
Academic Press, an imprint of Elsevier,
2014.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000Ia 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_ocn892239973 | ||
| 003 | OCoLC | ||
| 005 | 20231120111805.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 141004s2014 ne ob 000 0 eng d | ||
| 040 | |a EBLCP |b eng |e pn |c EBLCP |d N$T |d OPELS |d OCLCF |d OCLCQ |d OCLCO |d OCLCQ |d SAV |d DEBBG |d I9W |d D6H |d OCLCQ |d LUN |d S2H |d MERUC |d LOA |d TUHNV |d COM |d OCLCO |d OCLCQ |d OCLCO | ||
| 066 | |c (S | ||
| 020 | |a 9780128003725 |q (electronic bk.) | ||
| 020 | |a 0128003723 |q (electronic bk.) | ||
| 020 | |z 9780128001677 | ||
| 035 | |a (OCoLC)892239973 | ||
| 050 | 4 | |a RS400 | |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 082 | 0 | 4 | |a 615.19 |2 23 |
| 245 | 0 | 0 | |a Annual reports in medicinal chemistry. |n Volume 49 / |c Manoj C. Desai, editor-in-chief. |
| 260 | |a Amsterdam : |b Academic Press, an imprint of Elsevier, |c 2014. | ||
| 300 | |a 1 online resource (623 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 588 | 0 | |a Print version record. | |
| 504 | |a Includes bibliographical references. | ||
| 520 | |a Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry with an emphasis on emerging topics in the biological sciences that are expected to provide the basis for entirely new future therapies. Reviews on hot topics of interest in small molecule drug discovery heavily pursued by industrial research organizations</li><li>Provides preclinical information in the context of chemical structures. Knowledgeable section editors who evaluate invited reviews for scientific rigor. | ||
| 505 | 0 | |a Personal essays. My experiences in the pharmaceutical industry / John J. Baldwin -- Adventures in medical chemistry : a career in drug discovery / William J. Greenlee -- section 1. Central nervous system diseases. Natural and sysnthetic neuroactive steroid modulators of GABA and NMDA receptors / Gabriel Martinez-Botella ... [et al.] -- Development of LRRK2 kinase inhibitors for Parkinson's disease / Paul Galatsis ... [et al.] -- Stimulating neurotrophin receptors in the treatment of neurodegenerative disorders / Gunnar Nordvall and Pontus Forsell -- section 2. Cardiovascular and metabolic diseases. Small-molecule modulators of GPR40 (FFA1) / Sean P. Brown and Joshua P. Taygerly -- Recent advances in the development of P2Y12 receptor antagonists as antiplatelet agents / Allorie T. Caldwell and E. Blake Watkins -- Current approaches to the treatment of atrial fibrillation / Heather Finlay | |
| 508 | |a Mer receptor tyrosine kinase : therapeutic opportunities in oncology, virology, and cardiovascular indications / Xiaodong Wang and Stephen Frye -- section 7. Topics in drug design and discovery. Disease-modifying agents for the treatment of cystic fibrosis / Bradley D. Tait and John P. Miller --Advancements in stapled peptide drug discovery & development / Vincent Guerlavais and Tomi K. Sawyer -- Cytochrome P450 enzyme metabolites in lead discovery and development / Sylvie E. Kandel, Larry C. Wienkers and Jed N. Lampe -- 8. Case histories and NCEs. Case history : Forxiga (dapagliflozin), a potent selective SGLT2 inhibitor for treatment of diabetes / William N. Washburn -- Case history : Kalydeco (VS-770, ivacaftor), a CFTR potentiator for the treatment of patients with cystic fibrosis and the G551D-CFTR mutation / Sabine Hadida ... [et al.] -- Case history : Xeljanz (tofacitinib citrate), a first-in-class janus kinase inhibitor for the treatment of rheumatoid arthritis / Mark E. Flanagan ... [et al.] -- New chemical entities entering phase III trials in 2013 / Gregory T. Notte -- To market, to market : 2013 / Joanne Bronson ... [et al.]. | ||
| 650 | 0 | |a Clinical chemistry |v Periodicals. | |
| 650 | 0 | |a Pharmaceutical chemistry |v Periodicals. | |
| 650 | 6 | |a Chimie clinique |0 (CaQQLa)201-0016714 |v P�eriodiques. |0 (CaQQLa)201-0378307 | |
| 650 | 6 | |a Chimie pharmaceutique |0 (CaQQLa)201-0028674 |v P�eriodiques. |0 (CaQQLa)201-0378307 | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a Clinical chemistry |2 fast |0 (OCoLC)fst00864330 | |
| 650 | 7 | |a Pharmaceutical chemistry |2 fast |0 (OCoLC)fst01060115 | |
| 655 | 2 | |a Periodical |0 (DNLM)D020492 | |
| 655 | 7 | |a periodicals. |2 aat |0 (CStmoGRI)aatgf300026657 | |
| 655 | 7 | |a Periodicals |2 fast |0 (OCoLC)fst01411641 | |
| 655 | 7 | |a Periodicals. |2 lcgft | |
| 655 | 7 | |a P�eriodiques. |2 rvmgf |0 (CaQQLa)RVMGF-000001105 | |
| 700 | 1 | |a Desai, Manoj C., |e editor. | |
| 776 | 0 | 8 | |i Print version: |a Desai, Manoj C. |t Annual Reports in Medicinal Chemistry. |d Burlington : Elsevier Science, 2014 |z 9780128001677 |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780128001677 |z Texto completo |
| 880 | 8 | |6 505-00 |a section 3. Inflammation/pulmonary/GI diseases. Advances in the discovery of small-molecule IRAK4 inhibitors / John Hynes and Satheesh K. Nair -- H4 receptor antagonists and their potential therapeutic applications / David Burns ... [et al.] -- Urate crystal deposition disease and gout : new therapies for an old problem / Jean-Luc Girardet and Jeffrey N. Miner -- section 4. Oncology. p53-MDM2 and MDMX antagonists / Constantinos Neochoritis ... [et al.] -- Modulators of atypical protein kinase C as anticancer agents / Jonathan R.A. Roffey and Gregory R. Ott -- section 5. Infectious diseases. Advancement of cell wall inhibitors in Mycobacterium tuberculosis / Pravin S. Shirude ... [ et al.] -- Neucleosides and nucleotides for the treatment of viral disease / Michael J. Sofia -- Advances in inhibitors of penicillin-binding proteins and β-lactamases as antibacterial agents / Yong He ... [et al.] -- section 6. Topics in biology. Tumor microenvironment as target in cancer therapy / Reuven Reich, Claudiu T. Supuran, and Eli Breuer -- Novel screening paradigms for the identification of allosteric modulators and/or biased ligands for challenging G-protein-coupled receptors / Stephan Schann, Pascal Neuville, and Michel Bouvier | |